July 27 (Reuters) – Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
(Reporting by Lucie Barbier, editing by Milla Nissi-Prussak)
